Table 2 Information on donors—course of FQ treatment, symptoms of FQAD, effect of the experiment
From: Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy
Record | Age range | FQ name/days of treatment/dose in mg per day | Time since last FQ treatment | ADR after FQ immediate/delayed | FQAD symptoms constant/intermittent | Test result |
|---|---|---|---|---|---|---|
DONOR 1 | 30–39 | Lev/9 days/500 mg | 1 year | Immediate | Constant | Failed/no adherence |
DONOR 2 | 70–79 | Lev/2 days/500 mg | 10 years | Immediate | Constant | Failed/no adherence |
DONOR 3 | 50–59 | Lev/7 days/500 mg | 6 years | Delayed | Constant | Failed/no adherence |
DONOR 4 | 30–39 | Cip/10 days/500 mg | 1 year | Delayed | Constant | Failed/senescence before reprogramming |
DONOR 5 | 20–29 | Cip/30 days/1000 mg | 0.5 year | Delayed | Constant | Failed/senescence before reprogramming |
DONOR 6 | 30–39 | Cip otic/10 days/3 mg | 0.5 year | Delayed | Constant | Failed/senescence before reprogramming |
DONOR 7 | 40–49 | Cip otic/10 days/6 mg | 0.5 year | Delayed | Constant | Failed/senescence before reprogramming |
DONOR 8 | 60–69 | Cip/10 days/ 1000 mg | 10 years | Delayed | Constant | Failed/senescence after reprogramming |
DONOR 9 | 50–59 | Lev /5 days/ 500 mg | 9 years | Delayed | Constant | Complete |
DONOR 10 | 40–49 | Lev/24 days/500 mg | 5 years | Delayed | Constant | Failed/senescence after reprogramming |